The goal of this clinical trial is to test the impact of repeated intermittent short sleep, with short sleep maintained 5 days per week followed by 2 days of prolonged sleep, compared to daily adequate sleep, on energy balance and cardiometabolic risk. A secondary goal of this research is to determine if maintaining a constant midpoint of sleep while undergoing intermittent short sleep, leads to better outcomes than intermittent short sleep with a 2-hour delay in sleep midpoint. The aims of this research will be tested in the context of a 3-group, parallel-arm, outpatient intervention of 4 weeks in duration, in young-to-middle-aged adults (aged 18-49 years).
A large portion of the U.S. adult population reports insufficient sleep on a nightly basis. It has been shown that sustained insufficient sleep leads to adverse cardiometabolic risk profile and positive energy balance. However, sleep patterns in real life are not consistent over weeks. Individuals not obtaining sufficient sleep during the week may compensate by sleeping longer on weekends. The differences in sleep duration between week and weekend nights is approximately 1 hour, mostly due to delaying wake times rather than advancing bedtimes. A drawback of such behaviors is resultant change in sleep midpoint, which has been associated with adverse cardiometabolic health and obesity. However, very few studies have attempted to determine whether recovery sleep on weekends results in reversal of adverse health effects of insufficient sleep during the week. Available studies suggest that recovery sleep does not revert health markers to pre-sleep restriction (SR) levels. But these studies are short, usually involving only one cycle of SR followed by recovery sleep, and fail to use appropriate and robust statistical methods. Therefore, the goal of the current investigation is to evaluate the impact of repeated intermittent short sleep, with short sleep maintained 5 days/week followed by 2 days of recovery sleep, relative to daily adequate sleep, on energy balance and cardiometabolic risk markers. A secondary goal of this research is to determine if maintaining a constant sleep timing while undergoing intermittent short sleep, leads to better outcomes than intermittent short sleep in conjunction with shifts in sleep times.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Enrollment
72
Restricted sleep duration of \<5.5 h/night for 5 nights (SR) followed by 2 nights of 9.5 hours of time in bed (TIB) (recover sleep) each week.
2-hour delayed sleep timing.
Goal of ≥7 hours of sleep/night with 8 hours of time in bed (TIB).
Columbia University Irving Medical Center
New York, New York, United States
RECRUITINGFasting Plasma Glucose
Insulin resistance will be assessed by measuring fasting plasma glucose levels.
Time frame: Up to 4 weeks
Insulin Level
Insulin resistance will be assessed by measuring insulin levels.
Time frame: Up to 4 weeks
Morning Systolic and Diastolic Blood Pressure
Ambulatory blood pressure will be measured.
Time frame: Up to 4 weeks
Evening Systolic and Diastolic Blood Pressure
Ambulatory blood pressure will be measured.
Time frame: Up to 4 weeks
Fat mass
Body composition will be measured using Dual-energy X-ray absorptiometry (DXA) to determine fat mass.
Time frame: Up to 4 weeks
Low-density Lipoprotein (LDL) Level
Lipid panel will be assessed.
Time frame: Up to 4 weeks
High-density Lipoprotein (HDL) Level
Lipid panel will be assessed.
Time frame: Up to 4 weeks
Total Cholesterol Level
Lipid panel will be assessed.
Time frame: Up to 4 weeks
Triglyceride Level
Lipid panel will be assessed.
Time frame: Up to 4 weeks
C-reactive protein (CRP) Level
CRP will be measured as an inflammatory marker.
Time frame: Up to 4 weeks
Interleukin 6 (IL-6)
IL-6 will be measured as an inflammatory marker.
Time frame: Up to 4 weeks
Tumor necrosis factor alpha (TNF-alpha)
TNF-alpha will be measured as an inflammatory marker.
Time frame: Up to 4 weeks
Total daily energy expenditure
Energy expenditure will be measured using doubly-labeled water over 14 days
Time frame: Baseline and endpoint (4 weeks)
Energy Intake
Energy intake will be measured to assess diet quality using daily food records for 7 days.
Time frame: Baseline and endpoint (4 weeks)
Total Ghrelin
Total ghrelin will be assessed using radioimmunoassay (RIA).
Time frame: 2 hours post meal at baseline and endpoint (4 weeks)
Serum Leptin
Serum leptin will be measured using a double-antibody RIA.
Time frame: 2 hours post meal at baseline and endpoint (4 weeks)
Adiponectin Level
Adiponectin levels will be analyzed using RIA.
Time frame: Up to 4 weeks
Glucagon-like peptide 1 (GLP-1) Level
GLP-1 will be measured by RIA after plasma extraction with 95% ethanol.
Time frame: 2 hours post meal at baseline and endpoint (4 weeks)
Change in Nuclear factor kappa B (NFkB) Level
NFkB will be measured to assess endothelial cell inflammation.
Time frame: Baseline and endpoint (4 weeks)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.